Shunichi Negoro
Overview
Explore the profile of Shunichi Negoro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
3338
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamaguchi M, Tada H, Mitsudomi T, Seto T, Yokoi K, Katakami N, et al.
Int J Clin Oncol
. 2021 Aug;
26(12):2216-2223.
PMID: 34463869
Background: Adjuvant oral uracil-tegafur (UFT) has led to significantly longer postoperative survival among patients with non-small-cell lung cancer (NSCLC). Gemcitabine (GEM) monotherapy is also reportedly effective for NSCLC and has...
2.
Hattori Y, Kono Y, Itoh S, Inoue T, Urata Y, Kawa Y, et al.
BMC Cancer
. 2020 Feb;
20(1):115.
PMID: 32046667
Background: The aim of this study was to evaluate the efficacy and safety of nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC). Methods: Chemotherapy-naïve patients with...
3.
Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, et al.
Oncotarget
. 2018 Nov;
9(78):34765-34771.
PMID: 30410675
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their clinical benefit to more patients, a novel therapy to induce positive conversion...
4.
Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, et al.
BMC Cancer
. 2018 Oct;
18(1):946.
PMID: 30285770
Background: Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem....
5.
Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, et al.
Lung Cancer
. 2018 Oct;
124:65-70.
PMID: 30268482
Objectives: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (i.e., EGFR-TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the initial efficacy of EGFR-TKIs, the disease progression...
6.
Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, et al.
Cancer
. 2018 Sep;
124(19):3830-3838.
PMID: 30192383
Background: Preclinical studies suggested that the addition of bevacizumab could overcome acquired resistance (AR) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The aim of this study was...
7.
Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito A, et al.
Jpn J Clin Oncol
. 2018 Mar;
48(4):376-381.
PMID: 29528450
Background: Malignant pleural effusion is a commonly seen complication of malignancies such as lung and breast cancers. In Western countries, talc is frequently used as a standard therapeutic agent (pleurodesis...
8.
Yasuda Y, Urata Y, Tohnai R, Ito S, Kawa Y, Kono Y, et al.
Intern Med
. 2017 Dec;
57(9):1269-1272.
PMID: 29279482
We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg every 2 weeks for...
9.
Yasuda Y, Hattori Y, Tohnai R, Ito S, Kawa Y, Kono Y, et al.
Jpn J Clin Oncol
. 2017 Oct;
48(1):89-93.
PMID: 29036303
Background: The optimal chemotherapy regimen for non-small cell lung cancer patients with interstitial lung disease is unclear. We therefore investigated the safety and efficacy of carboplatin plus nab-paclitaxel as a...
10.
Tanioka M, Yamaguchi S, Shimada M, Nagao S, Takehara K, Nishimura M, et al.
Med Oncol
. 2017 Jul;
34(8):134.
PMID: 28681218
The aim of this study is to evaluate the outcome and safety of the multidisciplinary strategy using cisplatin plus dose-dense paclitaxel (dose-dense TP) before and after radical hysterectomy (RH) for...